Literature DB >> 26635038

STAT1 activation in association with JAK2 exon 12 mutations.

Anna L Godfrey1, Edwin Chen2, Charles E Massie2, Yvonne Silber2, Francesca Pagano2, Beatriz Bellosillo3, Paola Guglielmelli4, Claire N Harrison5, John T Reilly6, Frank Stegelmann7, Fontanet Bijou8, Eric Lippert9, Jean-Michel Boiron10, Konstanze Döhner7, Alessandro M Vannucchi4, Carlos Besses3, Anthony R Green11.   

Abstract

Entities:  

Keywords:  JAK2 exon 12; STAT1; activation; mutations

Mesh：

Substances：

Year:  2015        PMID： 26635038      PMCID： PMC4697901          DOI： 10.3324/haematol.2015.128546

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.

Authors:  Linda M Scott; Philip A Beer; Anthony J Bench; Wendy N Erber; Anthony R Green
Journal:  Br J Haematol       Date:  2007-11       Impact factor: 6.998

2.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.

Authors:  Francesco Passamonti; Chiara Elena; Susanne Schnittger; Radek C Skoda; Anthony R Green; François Girodon; Jean-Jacques Kiladjian; Mary Frances McMullin; Marco Ruggeri; Carles Besses; Alessandro M Vannucchi; Eric Lippert; Heinz Gisslinger; Elisa Rumi; Thomas Lehmann; Christina A Ortmann; Daniela Pietra; Cristiana Pascutto; Torsten Haferlach; Mario Cazzola
Journal:  Blood       Date:  2011-01-11       Impact factor: 22.113

4.  Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.

Authors:  Shubha Anand; Frances Stedham; Emma Gudgin; Peter Campbell; Philip Beer; Anthony R Green; Brian J P Huntly
Journal:  Blood       Date:  2011-06-08       Impact factor: 22.113

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

Authors:  Edwin Chen; Philip A Beer; Anna L Godfrey; Christina A Ortmann; Juan Li; Ana P Costa-Pereira; Catherine E Ingle; Emmanouil T Dermitzakis; Peter J Campbell; Anthony R Green
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

7.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

8.  A shift in the salt bridge interaction of residues D620 and E621 mediates the constitutive activation of Jak2-H538Q/K539L.

Authors:  Kavitha Gnanasambandan; Andrew T Magis; Peter P Sayeski
Journal:  Mol Cell Biochem       Date:  2012-05-15       Impact factor: 3.842

9.  JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.

Authors:  Anna L Godfrey; Edwin Chen; Francesca Pagano; Christina A Ortmann; Yvonne Silber; Beatriz Bellosillo; Paola Guglielmelli; Claire N Harrison; John T Reilly; Frank Stegelmann; Fontanet Bijou; Eric Lippert; Mary F McMullin; Jean-Michel Boiron; Konstanze Döhner; Alessandro M Vannucchi; Carlos Besses; Peter J Campbell; Anthony R Green
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

10.  MPN patients harbor recurrent truncating mutations in transcription factor NF-E2.

Authors:  Jonas S Jutzi; Ruzhica Bogeska; Gorica Nikoloski; Corina A Schmid; Thalia S Seeger; Frank Stegelmann; Sven Schwemmers; Albert Gründer; Jan C Peeken; Monika Gothwal; Julius Wehrle; Konrad Aumann; Kamar Hamdi; Christine Dierks; Wei Kamar Wang; Konstanze Döhner; Joop H Jansen; Heike L Pahl
Journal:  J Exp Med       Date:  2013-05-06       Impact factor: 14.307
View more
  3 in total

1.  Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.

Authors:  Ana Paula Azevedo; Susana N Silva; Alice Reichert; Fernando Lima; Esmeraldina Júnior; José Rueff
Journal:  Biomed Rep       Date:  2017-09-05

Review 2.  Mutant Calreticulin in the Myeloproliferative Neoplasms.

Authors:  Daniel Prins; Carlos González Arias; Thorsten Klampfl; Jacob Grinfeld; Anthony R Green
Journal:  Hemasphere       Date:  2020-01-15

Review 3.  Molecular pathogenesis of the myeloproliferative neoplasms.

Authors:  Graeme Greenfield; Mary Frances McMullin; Ken Mills
Journal:  J Hematol Oncol       Date:  2021-06-30       Impact factor: 17.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.